Fortacin

RSS

lidocaine / prilocaine

Authorised
This medicine is authorised for use in the European Union.

Overview

Fortacin is used to treat men with primary (lifelong) premature ejaculation (when ejaculation regularly occurs before, or too early during, penetration).

Fortacin contains the active substances lidocaine and prilocaine.

This EPAR was last updated on 01/09/2021

Authorisation details

Product details
Name
Fortacin
Agency product number
EMEA/H/C/002693
Active substance
  • lidocaine
  • prilocaine
International non-proprietary name (INN) or common name
  • lidocaine
  • prilocaine
Therapeutic area (MeSH)
Sexual Dysfunction, Physiological
Anatomical therapeutic chemical (ATC) code
N01BB20
Publication details
Marketing-authorisation holder
Recordati Ireland Ltd.
Revision
10
Date of issue of marketing authorisation valid throughout the European Union
15/11/2013
Contact address

Raheens East
Ringaskiddy, Co. Cork,
Ireland

Product information

27/07/2021 Fortacin - EMEA/H/C/002693 - IA/0033

Product information documents contain:

You can find product information documents for centrally authorised human medicines on this website. For centrally authorised veterinary medicines authorised or updated from February 2022, see the Veterinary Medicines Information website.

Pharmacotherapeutic group

Anesthetics

Therapeutic indication

Treatment of primary premature ejaculation in adult men.

Assessment history

How useful was this page?

Add your rating
Average
1 rating